Big Data for outcomes and clinical research:

major advance or improvement needed

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Creation of Big Data repositories is now emphasized at virtually all research institutions and the NIH, but the number of publications describing patient outcomes from these sources appears modest.1 Why is this so; what factors limit what should be a hugely productive resource, and how can we improve the impact of this use of Big Data? Why does this issue require greater physician engagement and understanding to solve? The integration of clinical, laboratory, and financial data is required to describe disease and treatment outcomes as well as treatment value.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Roy B. Jones
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX
Amar Chahal
Chief operating officer, Velos Inc.
Dianne Reeves, MD
Retired associate director, Center for Biomedical Informatics and Information Technology, NCI
Gregory H. Jones
Resident, University of Texas School of Medicine
Charles S. Martinez
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX
Table of Contents

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
Roy B. Jones
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX
Amar Chahal
Chief operating officer, Velos Inc.
Dianne Reeves, MD
Retired associate director, Center for Biomedical Informatics and Information Technology, NCI
Gregory H. Jones
Resident, University of Texas School of Medicine
Charles S. Martinez
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login